Share
8 Posts.
lightbulb Created with Sketch. 0
clock Created with Sketch.
07/04/18
00:04
Share
Originally posted by Noda
↑
I think the challenge for Neuren is what's next. Once Trofinetide is licenced (and I am assuming this includes some deal around NNZ-2591) especially if it is for all indications, what else do they have in the development pipeline? What are the future growth opportunities?
For me TBI stands out as the big one. So far it hasn't been successful but the potential is huge, putting Rett and Fragile-X in the shade. How do you value that in an 'all indications' deal?
I think a full acquisition either up front or earn-out will work best. Neuren is a 1 trick pony set up to bring a small product group to market. Doing that and cashing in makes the most sense IMO.
The other option is to licence for limited indications and leave Neuren to pursue TBI either alone or in partnership to expand the value proposition. Once TBI is done (either successfully or not) I think Neuren has limited value creating prospects and would be better off selling up.
Neuren probably doesn't offer much technical expertise beyond this point that big pharma can't handle. They have developed the molecule and the manufacturing method. Big pharma has much more horsepower to test and validate every possible potential application Rett through Autism through TBI etc.
This makes me think they will want to buy out as they could get it now at a price that they can possibly expand value on. Imagine if it treated regular Autism? The market would be a blockbuster.
Expand
Objectives to be achieved and strategies to achieve them, as soon as possible.
This are the fundamental A B C for a future very great Company !!!